KPMA splits over president’s nomination

Published: 2012-02-08 06:58:00

Updated: 2012-02-08 06:58:00

A controversy is quietly brewing within the Korea Pharmaceutical Manufacturers Association ahead of its next president’s nomination on the board of directors meeting on Feb. 16.

The key member of KPMA leadership team agreed unanimously to re-appoint Rhu Duk-hee, incumbent KPMA president, as it...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK